International consensus statement on the peri-operative management of direct oral anticoagulants in cardiac surgery

Anaesthesia

Volumn 73, Issue 12, 2018, Pages 1535-1545

  Erdoes, G ^a   Martinez Lopez De Arroyabe, B ^b   Bolliger, D ^c   Ahmed, A B ^d,e   Koster, A ^f   Agarwal, S ^g   Boer, C ^h   von Heymann, C ⁱ  

^a UNIVERSITY OF BERN   (Switzerland)

^b UNIVERSITY HOSPITAL OF TRIESTE   (Italy)

^c UNIVERSITY HOSPITAL BASEL   (Switzerland)

^d UNIVERSITY HOSPITALS OF LEICESTER NHS TRUST   (United Kingdom)

^e UNIVERSITY OF LEICESTER   (United Kingdom)

^f RUHR UNIVERSITY BOCHUM   (Germany)

^g LIVERPOOL HEART AND CHEST HOSPITAL   (United Kingdom)

^h VU UNIVERSITY MEDICAL CENTER   (Netherlands)

ⁱ VIVANTES KLINIKUM IM FRIEDRICHSHAIN   (Germany)

Author keywords

bleeding; cardiac surgery; cardiopulmonary bypass; direct oral anticoagulants; haemostasis; transfusion

Indexed keywords

ACTIVATED PROTHROMBIN COMPLEX; ANDEXANET ALFA; ANTICOAGULANT AGENT; ANTIDOTE; APIXABAN; BLOOD CLOTTING FACTOR 10A INHIBITOR; BLOOD CLOTTING FACTOR 7A; CIRAPARANTAG; DABIGATRAN; DABIGATRAN ETEXILATE; EDOXABAN; FIBRINOGEN CONCENTRATE; HEMOSTATIC AGENT; HEPARIN; IDARUCIZUMAB; LOW MOLECULAR WEIGHT HEPARIN; PROTHROMBIN COMPLEX; RIVAROXABAN; TRANEXAMIC ACID; WARFARIN;

ANESTHESIOLOGY; ANTICOAGULATION; BLEEDING; BLEEDING TENDENCY; BLOOD TRANSFUSION; CARDIOPULMONARY BYPASS; CEREBROVASCULAR ACCIDENT; CLINICAL PRACTICE; CONSENSUS DEVELOPMENT; DRUG APPROVAL; DRUG DOSE REDUCTION; DRUG MECHANISM; DRUG WITHDRAWAL; ELECTIVE SURGERY; ELIMINATION HALF-LIFE; EUROPE; HEART SURGERY; HEART TRANSPLANTATION; HEMODIALYSIS; HEMOSTASIS; HIGH RISK PATIENT; HIGH RISK SURGERY; HUMAN; LOW DRUG DOSE; LUNG EMBOLISM; MEDICAL RESEARCH; MEDICAL SOCIETY; OPERATIVE BLOOD LOSS; PATIENT MONITORING; PEER REVIEW; PEROPERATIVE CARE; PRACTICE GUIDELINE; RECOMMENDED DRUG DOSE; REVIEW; SURGICAL PATIENT; SYSTEMATIC REVIEW; THROMBOEMBOLISM; TREATMENT OUTCOME; VENOUS THROMBOEMBOLISM; CONSENSUS; DRUG UTILIZATION; PERIOPERATIVE PERIOD; PROCEDURES; STANDARDS; STATISTICS AND NUMERICAL DATA; THORAX SURGERY;

ANTICOAGULANTS; CARDIAC SURGICAL PROCEDURES; CONSENSUS; DRUG UTILIZATION; HEMORRHAGE; HUMANS; PERIOPERATIVE CARE; THORACIC SURGERY;

EID: 85053875892     PISSN: 00032409     EISSN: 13652044     Source Type: Journal    
DOI: 10.1111/anae.14425     Document Type: Review

References (67)

1. Mearns ES, Kohn CG, Song JS, et al. Meta-analysis to assess the quality of international normalized ratio control and associated outcomes in venous thromboembolism patients. Thrombosis Research 2014; 134: 310–19.
2. Schein JR, White CM, Nelson WW, Kluger J, Mearns ES, Coleman CI. Vitamin K antagonist use: evidence of the difficulty of achieving and maintaining target INR range and subsequent consequences. Thrombosis Journal 2016; 14: 14.
3. Holm J, Lindh JD, Andersson ML, Mannheimer B. The effect of amiodarone on warfarin anticoagulation: a register-based nationwide cohort study involving the Swedish population. Journal of Thrombosis and Haemostasis 2017; 15: 446–53.
4. Godier A, Dincq AS, Martin AC, et al. Predictors of pre-procedural concentrations of direct oral anticoagulants: a prospective multicentre study. European Heart Journal 2017; 38: 2431–9.
5. Doherty JU, Gluckman TJ, Hucker WJ, et al. 2017 ACC expert consensus decision pathway for periprocedural management of anticoagulation in patients with nonvalvular atrial fibrillation: a report of the american college of cardiology clinical expert consensus document task force. Journal of the American College of Cardiology 2017; 69: 871–98.
6. Heidbuchel H, Verhamme P, Alings M, et al. Updated European heart rhythm association practical guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation. Europace 2015; 17: 1467–507.
7. Cuker A, Siegal D. Monitoring and reversal of direct oral anticoagulants. Hematology. American Society of Hematology. Education Program 2015; 2015: 117–24.
8. Cuker A, Siegal DM, Crowther MA, Garcia DA. Laboratory measurement of the anticoagulant activity of the non-vitamin K oral anticoagulants. Journal of the American College of Cardiolology 2014; 64: 1128–39.
9. Douxfils J, Mullier F, Robert S, Chatelain C, Chatelain B, Dogne JM. Impact of dabigatran on a large panel of routine or specific coagulation assays. Laboratory recommendations for monitoring of dabigatran etexilate. Thrombosis and Haemostasis 2012; 107: 985–97.
10. Mani H, Hesse C, Stratmann G, Lindhoff-Last E. Rivaroxaban differentially influences ex vivo global coagulation assays based on the administration time. Thrombosis and Haemostasis 2011; 106: 156–64.
11. Gosselin RC, Adcock DM, Bates SM, et al. International council for standardization in haematology (ICSH) recommendations for laboratory measurement of direct oral anticoagulants. Thrombosis and Haemostasis 2018; 118: 437–50.
12. Samuelson BT, Cuker A, Siegal DM, Crowther M, Garcia DA. Laboratory assessment of the anticoagulant activity of direct oral anticoagulants – a systematic review. Chest 2017; 151: 127–38.
13. Ebner M, Birschmann I, Peter A, et al. Point-of-care testing for emergency assessment of coagulation in patients treated with direct oral anticoagulants. Critical Care 2017; 21: 32.
14. Levy JH, Ageno W, Chan NC, Crowther M, Verhamme P, Weitz JI. When and how to use antidotes for the reversal of direct oral anticoagulants: guidance from the SSC of the ISTH. Journal of Thrombosis and Haemostasis 2016; 14: 623–7.
15. Pernod G, Albaladejo P, Godier A, et al. Management of major bleeding complications and emergency surgery in patients on long-term treatment with direct oral anticoagulants, thrombin or factor-Xa inhibitors: proposals of the working group on perioperative haemostasis (GIHP) – March 2013. Archives of Cardiovascular Diseases 2013; 106: 382–93.
16. Stangier J, Stahle H, Rathgen K, Fuhr R. Pharmacokinetics and pharmacodynamics of the direct oral thrombin inhibitor dabigatran in healthy elderly subjects. Clinical Pharmacokinetics 2008; 47: 47–59.
17. Breuer G, Weiss DR, Ringwald J. ‘New’ direct oral anticoagulants in the perioperative setting. Current Opinion in Anaesthesiology 2014; 27: 409–19.
18. Augoustides JG. Advances in anticoagulation: focus on dabigatran, an oral direct thrombin inhibitor. Journal of Cardiothoracic and Vascular Anesthesia 2011; 25: 1208–12.
19. Stangier J, Rathgen K, Stahle H, Mazur D. Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: an open-label, parallel-group, single-centre study. Clinical Pharmacokinetics 2010; 49: 259–68.
20. Leitch J, van Vlymen J. Managing the perioperative patient on direct oral anticoagulants. Canadian Journal of Anesthesia 2017; 64: 656–72.
21. Kozek-Langenecker SA, Ahmed AB, Afshari A, et al. Management of severe perioperative bleeding: guidelines from the European Society of Anaesthesiology. European Journal of Anaesthesiology 2017; 34: 332–95.
22. Pollack CV Jr, Reilly PA, van Ryn J, et al. Idarucizumab for dabigatran reversal – full cohort analysis. New England Journal of Medicine 2017; 377: 431–41.
23. Raval AN, Cigarroa JE, Chung MK, et al. Management of patients on non-vitamin k antagonist oral anticoagulants in the acute care and periprocedural setting: a scientific statement from the american heart association. Circulation 2017; 135: e604–e633.
24. Pollack CV Jr, Reilly PA, Weitz JI. Dabigatran reversal with idarucizumab. New England Journal of Medicine 2017; 377: 1691–2.
25. Rimsans J, Rhoten M, Sylvester K, Singh SK, Connors JM. Idarucizumab for urgent reversal of dabigatran for heart transplant: a case report. American Journal of Hematology 2017; 92: E34–E35.
26. Ansell JE, Bakhru SH, Laulicht BE, et al. Use of PER977 to reverse the anticoagulant effect of edoxaban. New England Journal of Medicine 2014; 371: 2141–2.
27. Wanek MR, Horn ET, Elapavaluru S, Baroody SC, Sokos G. Safe use of hemodialysis for dabigatran removal before cardiac surgery. Annals of Pharmacotherapy 2012; 46: e21.
28. Warkentin TE, Margetts P, Connolly SJ, Lamy A, Ricci C, Eikelboom JW. Recombinant factor VIIa (rFVIIa) and hemodialysis to manage massive dabigatran-associated postcardiac surgery bleeding. Blood 2012; 119: 2172–4.
29. Marchetti G, Giuliani E, Urbinati S, Barbieri A. Dabigatran anticoagulation and Stanford type A aortic dissection: not a lethal coincidence. Acta Anaesthesiologica Scandinavica 2016; 60: 544.
30. Schulman S, Carrier M, Lee AY, et al. Perioperative management of dabigatran: a prospective cohort study. Circulation 2015; 132: 167–73.
31. Hassan K, Bayer N, Schlingloff F, et al. Bleeding complications after use of novel oral anticoagulants in patients undergoing cardiac surgery. Annals of Thoracic Surgery 2018; 105: 702–8.
32. Belli EV, Lee T. Idarucizumab (Praxbind) for reversal of pradaxa prior to emergent repair of contained ruptured transverse arch aneurysm. Annals of Cardiac Anesthesia 2017; 20: 369–71.
33. Levy JH, Faraoni D, Spring JL, Douketis JD, Samama CM. Managing new oral anticoagulants in the perioperative and intensive care unit setting. Anesthesiology 2013; 118: 1466–74.
34. Dubois V, Dincq AS, Douxfils J, et al. Perioperative management of patients on direct oral anticoagulants. Thrombosis Journal 2017; 15: 14.
35. Sunkara T, Ofori E, Zarubin V, Caughey ME, Gaduputi V, Reddy M. Perioperative management of direct oral anticoagulants (DOACs): a systemic review. Health Services Insights 2016; 9: 25–36.
36. Lai A, Davidson N, Galloway SW, Thachil J. Perioperative management of patients on new oral anticoagulants. British Journal of Surgery 2014; 101: 742–9.
37. Siegal DM, Curnutte JT, Connolly SJ, et al. Andexanet alfa for the reversal of factor Xa inhibitor activity. New England Journal of Medicine 2015; 373: 2413–24.
38. Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. New England Journal of Medicine 2011; 365: 883–91.
39. Gibson CM, Chakrabarti AK, Mega J, et al. Reduction of stent thrombosis in patients with acute coronary syndromes treated with rivaroxaban in ATLAS-ACS 2 TIMI 51. Journal of the American College of Cardiology 2013; 62: 286–90.
40. Abouchakra L, Khabbaz Z, Abouassi S, Badaoui G. Rivaroxaban for treatment of heparin-induced thrombocytopenia after cardiac surgery: a case report. Journal of Thoracic and Cardiovascular Surgery 2015; 150: e19–e20.
41. Bene J, Auffray JL, Auffret M, Caron J, Gautier S. Aortic dissection during rivaroxaban therapy: a challenging care. Acta Anaesthesiologica Scandinavica 2015; 59: 268.
42. Wong PC, Crain EJ, Xin B, et al. Apixaban, an oral, direct and highly selective factor Xa inhibitor: in vitro, antithrombotic and antihemostatic studies. Journal of Thrombosis and Haemostasis 2008; 6: 820–9.
43. Di Biase L, Callans D, Haeusler KG, et al. Rationale and design of AXAFA-AFNET 5: an investigator-initiated, randomized, open, blinded outcome assessment, multi-centre trial to comparing continuous apixaban to vitamin K antagonists in patients undergoing atrial fibrillation catheter ablation. Europace 2017; 19: 132–8.
44. Seeger J, Gonska B, Rodewald C, Rottbauer W, Wohrle J. Apixaban in patients with atrial fibrillation after transfemoral aortic valve replacement. Journal of the American College of Cardiology Cardiovascular Interventions 2017; 10: 66–74.
45. Kubisz P, Stanciakova L, Dobrotova M, Samos M, Mokan M, Stasko J. Apixaban – metabolism, pharmacologic properties and drug interactions. Current Drug Metabolism 2017; 18: 609–21.
46. Hurst KV, O'Callaghan JM, Handa A. Quick reference guide to apixaban. Vascular Health Risk Management 2017; 13: 263–7.
47. Duncan L, Heathcote J, Djurdjev O, Levin A. Screening for renal disease using serum creatinine: who are we missing? Nephrology Dialysis Transplantation 2001; 16: 1042–6.
48. Swedko PJ, Clark HD, Paramsothy K, Akbari A. Serum creatinine is an inadequate screening test for renal failure in elderly patients. Archives of Internal Medicine 2003; 163: 356–60.
49. Wang X, Mondal S, Wang J, et al. Effect of activated charcoal on apixaban pharmacokinetics in healthy subjects. American Journal of Cardiovascular Drugs 2014; 14: 147–54.
50. Dickneite G, Hoffman M. Reversing the new oral anticoagulants with prothrombin complex concentrates (PCCs): what is the evidence? Thrombosis and Haemostasis 2014; 111: 189–98.
51. Liotta EM, Levasseur-Franklin KE, Naidech AM. Reversal of the novel oral anticoagulants dabigatran, rivoraxaban, and apixaban. Current Opinion in Critical Care 2015; 21: 127–33.
52. Song Y, Wang Z, Perlstein I, et al. Reversal of apixaban anticoagulation by four-factor prothrombin complex concentrates in healthy subjects: a randomized three-period crossover study. Journal of Thrombosis and Haemostasis 2017; 15: 2125–37.
53. Giugliano RP, Ruff CT, Braunwald E, et al. Edoxaban versus warfarin in patients with atrial fibrillation. New England Journal of Medicine 2013; 369: 2093–104.
54. Fuji T, Fujita S, Kawai Y, et al. Efficacy and safety of edoxaban versus enoxaparin for the prevention of venous thromboembolism following total hip arthroplasty: STARS J-V. Thrombosis Journal 2015; 13: 27.
55. Fuji T, Fujita S, Kawai Y, et al. Safety and efficacy of edoxaban in patients undergoing hip fracture surgery. Thrombosis Research 2014; 133: 1016–22.
56. Fuji T, Wang CJ, Fujita S, Kawai Y, Kimura T, Tachibana S. Safety and efficacy of edoxaban, an oral factor xa inhibitor, for thromboprophylaxis after total hip arthroplasty in Japan and Taiwan. Journal of Arthroplasty 2014; 29: 2439–46.
57. Buller HR, Decousus H, Grosso MA, et al. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. New England Journal of Medicine 2013; 369: 1406–15.
58. Bathala MS, Masumoto H, Oguma T, He L, Lowrie C, Mendell J. Pharmacokinetics, biotransformation, and mass balance of edoxaban, a selective, direct factor Xa inhibitor, in humans. Drug Metabolism and Disposition 2012; 40: 2250–5.
59. Bounameaux H, Camm AJ. Edoxaban: an update on the new oral direct factor Xa inhibitor. Drugs 2014; 74: 1209–31.
60. Zahir H, Brown KS, Vandell AG, et al. Edoxaban effects on bleeding following punch biopsy and reversal by a 4-factor prothrombin complex concentrate. Circulation 2015; 131: 82–90.
61. Carnicelli AP, de Caterina R, Halperin JL, et al. Edoxaban for the prevention of thromboembolism in patients with atrial fibrillation and bioprosthetic valves. Circulation 2017; 135: 1273–5.
62. Mar PL, Familtsev D, Ezekowitz MD, Lakkireddy D, Gopinathannair R. Periprocedural management of anticoagulation in patients taking novel oral anticoagulants: review of the literature and recommendations for specific populations and procedures. International Journal of Cardiology 2016; 202: 578–85.
63. Tomaselli GF, Mahaffey KW, Cuker A, et al. 2017 ACC expert consensus decision pathway on management of bleeding in patients on oral anticoagulants: a report of the american college of cardiology task force on expert consensus decision pathways. Journal of the American College of Cardiology 2017; 70: 3042–67.
64. Douketis JD, Healey JS, Brueckmann M, et al. Perioperative bridging anticoagulation during dabigatran or warfarin interruption among patients who had an elective surgery or procedure. Substudy of the RE-LY trial. Thrombosis and Haemostasis 2015; 113: 625–32.
65. Spyropoulos AC, Al-Badri A, Sherwood MW, Douketis JD. Periprocedural management of patients receiving a vitamin K antagonist or a direct oral anticoagulant requiring an elective procedure or surgery. Journal of Thrombosis and Haemostasis 2016; 14: 875–85.
66. Kubitza D, Roth A, Becka M, et al. Effect of hepatic impairment on the pharmacokinetics and pharmacodynamics of a single dose of rivaroxaban, an oral, direct Factor Xa inhibitor. British Journal of Clinical Pharmacology 2013; 76: 89–98.
67. Beyer-Westendorf J, Gelbricht V, Förster K, et al. Peri-interventional management of novel oral anticoagulants in daily care: results from the prospective Dresden NOAC registry. European Heart Journal 2014; 35: 1888–96.